Science & Innovation

Pipeline

Dorzagliatin

mGluR5

Poster and Presentation

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information (2552.HK)

Corporate Communications

Portfolio Advisory Board

Senior Scientific Advisory Board

Media

Company News

Jan 23

2019

Hua Medicine Announces Update on China IP of Dorzagliatin and Progress of Phase III Trials.

Hua Medicine (HKEX: 2552), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, announced today that the China National Intellectual Property Administration (CNIPA) has issued a patent on a controlled release formulation of dorzagliatin.

Sep 14

2018

Hua Medicine Successfully Completes Initial Public Offering and Listing on the Hong Kong Stock Exchange

Hua Medicine, a China-based drug development company with a focus on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, successfully completed its initial public offering, or IPO, and listing on the Hong Kong Stock Exchange.

Aug 09

2018

Hua Medicine hires AstraZeneca China Diabetes Veteran as VP, Head of Commercial Strategy and Marketing

Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, announced Wenjie Xu, an experienced sales & marketing veteran in China, joins Hua Medicine as VP, Head of Commercial Strategy and Marketing.

Mar 27

2018

Hua Medicine Raises $117.4 Million in Series D & Series E Financing

Hua Medicine, a clinical-stage drug development company developing novel therapies for the treatment of Type 2 diabetes, announced the closing of a combined Series D & Series E financing of US$ 117.4 million.

Dec 22

2017

Bank of America Merrill Lynch Investment Banking Veteran Joins Hua Medicine as CFO

Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, announced that George Lin, a seasoned investment banker in the U.S. and Asia, joined Hua Medicine as EVP and Chief Financial Officer.

Oct 17

2016

Hua Medicine Announces First-Ever Successful Phase 2 Monotherapy Trial for New Class of Diabetes Drug

Hua Medicine, a leading clinical stage biotech company in Shanghai, announced today positive results in the first-ever successful Phase 2 monotherapy trial of a novel drug class called glucokinase activators (GKA). The company's 4th-generation GKA, HMS5552, targets one of the key enzymes (GK) that act as a 'glucose sensor' and regulates the pathways for carbohydrate metabolism.

Sep 22

2016

Hua Medicine Successfully Completes 12-week Phase 2 Trial of Novel GKA Diabetes Drug

Hua Medicine, a leading clinical stage biotech company in Shanghai, announced the successful completion of its Phase II clinical trial for HMS5552, a novel 1st-in-class Glucokinase Activator (GKA) for the treatment of diabetes.

Apr 22

2016

Hua Medicine Raises $50 Million Series C Financing in Oversubscribed Round

Hua Medicine, a clinical-stage company developing first-in-class and best-in-class therapies for China and the world-wide market, announced the closing of a combined US Dollar- and Chinese Renminbi-denominated investment of approximately $50 million in Series C financing.

Aug 11

2015

Hua Medicine’s GKA Diabetes Drug Demonstrates High Efficacy in 4-week Phase 1c Trial

Hua Medicine announced today its third successful clinical trial of lead program HMS5552, a novel glucokinase activator (GKA) treatment for Type 2 diabetes (T2DM). This latest Phase 1c trial demonstrated an impressive 1% HbA1c average reduction in patients compared to their baseline blood levels after only 4 weeks of treatment.

About Us

Company Overview

Company History

Leadership Team

Portfolio Advisory Board

Senior Scientific Advisory Board

Partner

Media center

Research & Development

Inovation

Pipeline

Dorzagliatin

mGluR5

Company Publications

Peer Reviewed Publications

Investor Relations

Corporate Governance

Financial Report

Announcements & Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock information

Media

Company News

Media Releases

Video

Careers

Culture

Join Us

Product

HuaTangNing(華堂寧®)

Focus Us

滬公網(wǎng)安備 31011502013809號(hào) Privacy Statement Terms of Use

How we use cookies

Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.